Aquestive Therapeutics to Present at Four Investor Conferences in September 2026
Event summary
- Aquestive Therapeutics will participate in four investor conferences in September 2026.
- Key events include a fireside chat at the Cantor Healthcare Conference on September 9th and a presentation at the H.C. Wainwright Conference on September 14th.
- Webcasts of the fireside chat and presentation will be available on the company's investor relations website.
- Aquestive is advancing Anaphylm™ and AQST-108 through clinical development.
The big picture
Aquestive Therapeutics' participation in multiple investor conferences underscores its focus on engaging with the investment community amid key clinical developments. The company's emphasis on innovative drug delivery technologies positions it within the broader trend of pharmaceutical firms leveraging advanced science to address unmet medical needs. The strategic significance lies in Aquestive's ability to balance its proprietary product development with its role as a Contract Development and Manufacturing Organization (CDMO).
What we're watching
- Clinical Progress
- How the advancement of Anaphylm™ and AQST-108 will impact Aquestive's market position.
- Investor Sentiment
- Whether the upcoming investor conferences will boost Aquestive's stock performance.
- Regulatory Approvals
- The pace at which Aquestive can secure FDA approvals for its product candidates.
Related topics